GlassScriptPhysician profile
Michael C White
NPI 1780673707
$5,870.24
in general payments reported to CMS, 2019-2025
23 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $2,163 · 2023: $715 · 2024: $1,282 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,266.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,713.69 | 2021-2025 | Minimed 780g, Minimed 770g |
| Tandem Diabetes Care, INC. | $684.32 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $392.97 | 2021-2025 | Freestyle Libre 3 |
| Insulet Corporation | $322.22 | 2022-2024 | Omnipod |
| Corcept Therapeutics | $299.11 | 2021-2025 | Korlym |
| Lilly USA, LLC | $179.03 | 2024 | Mounjaro, Zepbound |
| Enterra Medical, INC. | $156.46 | 2025 | |
| Janssen Biotech, INC. | $148.67 | 2024 | Erleada, Akeega |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.10 | 2023-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $135.68 | 2022 | |
| Ascendis Pharma Endocrinology INC | $134.16 | 2025 | Yorvipath |
| Dexcom, INC. | $128.72 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $76.77 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $64.98 | 2021-2025 | Isturisa |
| Xeris Pharmaceuticals, INC. | $54.41 | 2021-2025 | Recorlev |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $45.65 | 2025 | Twiist |
| Ibsa Pharma INC. | $42.43 | 2021 | |
| Sanofi-Aventis U.S. LLC | $33.06 | 2021-2022 | |
| Amgen INC. | $31.54 | 2021-2022 | |
| Averitas Pharma INC. | $26.67 | 2024 | Qutenza |
| Eusa Pharma (US) LLC | $23.05 | 2022 | |
| Echosens North America, INC. | $17.22 | 2022 | |
| Zealand Pharma US, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.